| HCC in non-cirrhotic NAFLD n (%) | HCC in cirrhotic NAFLD n (%) | P value |
---|---|---|---|
Total | 170 (100) | 940 (100) | Â |
Gender |  |  | < 0.397 |
 Male gender | 100 (58.8) | 520 (55.3) |  |
 Female gender | 70 (41.2) | 420 (44.7) |  |
Age group | Â | Â | 0.008 |
 Age > 65 years | 110 (64.7) | 700 (74.5) |  |
 Age 18–65 years | 60 (35.3) | 240 (25.5) |  |
Race |  |  | < 0.001 |
 Non-Hispanic white | 130 (76.4) | 800 (85.1) |  |
 Non-Hispanic black | 20 (11.8) | 20 (2.1) |  |
 Hispanic | 20 (11.8) | 120 (12.8) |  |
Comorbidities | Â | Â | Â |
 Obesity | 70 (41.2) | 490 (52.1) | 0.009 |
 Morbid obesity | 20 (11.8) | 240 (25.5) | < 0.001 |
 Diabetes mellitus | 100 (58.8) | 700 (74.5) | < 0.001 |
 Hypertension | 140 (82.4) | 770 (81.9) | 0.891 |
 Hyperlipidemia | 130 (76.5) | 590 (62.8) | 0.001 |
Smoker | 30 (17.6) | 230 (24.5) | 0.053 |
Laboratory data | Â | Â | Â |
 High ALT | 110 (64.7) | 600 (63.8) | 0.827 |
Medication use | Â | Â | Â |
 Statin | 100 (58.8) | 450 (47.9) | 0.009 |
 ACEI or ARBs | 120 (70.6) | 610 (64.9) | 0.150 |
 Metformin | 60 (35.3) | 390 (41.5) | 0.130 |
 Sulfonylurea | 40 (23.5) | 280 (39.8) | 0.097 |
 Thiazolidinedione | 0 (0) | 70 (7.4) | < 0.001 |
 Insulin | 80 (47.0) | 620 (66.0) | < 0.001 |
Liver decompensation | – | 675 (71.8) |  |